Evotec SE - ADR
EVO
Get informed when a big investor buys or sells
+ FollowMarket Cap$799.29M
Close$
$-3.37
337.6% downside
Current Fair Value
337.6% downsideOvervalued by 337.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $799.29 Million |
|---|---|
| Enterprise Value | $926.80 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.28 |
| Beta | 1.26 |
| Outstanding Shares | 355,527,580 |
Return
| Return on Equity | -30.04% |
|---|---|
| Return on Assets | -12.70% |
| Return on Invested Capital | -10.09% |
Valuation & Multiples
| P/E Ratio | -2.5 |
|---|---|
| PEG | -27.55 |
| Price to Sales | 0.71 |
| Price to Book Ratio | 1.42 |
| Enterprise Value to Revenue | 1.29 |
| Enterprise Value to EBIT | -7.28 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.51 |
| Debt to Equity | 0.71 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
$174.57 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$160.60 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.91%▼ 1.38% |
|---|---|
| Total Invested | $9.08M▼ 55.25% |
| Investors Holding | 35▼ 11.00% |
ESG Score
No data
About Evotec SE
4,553 employees
CEO: Werner Lanthaler Evotec SE operates as a global collaborative partner for the pharmaceutical and biotechnology industries, focusing on drug discovery and development. The firm is actively engaged in advancing medicinal products spanning a diverse range o...